ERICK MENEZES XAVIER
Índice h a partir de 2011
2
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
- Increased Risk of for Cytomegalovirus Reactivation after Allogeneic HSCT in T-Cell Depleted Patients(2020) MOLLA, Vinicius Campos; AZEVEDO, Roberta; RAMOS, Jessica Fernandes; PONCIANO, Danilo Belchior; MORAES, Pedro Henrique Arruda de; FONSECA, Ana Rita Da; SEIWALD, Maria Cristina Nunez; SERPA, Mariana; FERREIRA, Aliana Meneses; SZOR, Roberta Shcolnik; LEONEL, Rayana Bomfim; XAVIER, Erick Menezes; ROCHA, Vanderson; TUCUNDUVA, Luciana; NOVIS, Yana; NUCCI, Marcio; KALLAS, Esper; ARRAIS, Celso
conferenceObject High-dose chemotherapy with autologous stem cell transplant (HDCT) for patients (pts) with advanced germ-cell tumors (aGCT): Real-world evidence from a tertiary cancer center in Brazil.(2023) POLHO, Gabriel Berlingieri; CUNHA, Mateus Trinconi; XAVIER, Erick Menezes; SILVA, Jamile Almeida; HIDALGO FILHO, Cassio Murilo Trovo; CRUSOE, Nathalia de Souza Del Rey; ATANAZIO, Marcelo Junqueira; HORITA, Vivian; FREITAS, Guilherme Fialho de; MUNIZ, David Queiroz Borges; ROCHA, Vanderson Geraldo; MOTA, Jose Mauricio- Umbilical Cord Mesenchymal Stromal Cells for Steroid-Refractory Acute Graft-versus-Host Disease(2023) DONADEL, Camila Derminio; PIRES, Bruno Garcia; ANDRE, Nathalia Cristine; COSTA, Thalita Cristina Mello; ORELLANA, Maristela Delgado; CARUSO, Samia Rigotto; SEBER, Adriana; GINANI, Valeria Cortez; GOMES, Alessandra Araujo; NOVIS, Yana; BARROS, George Mauricio Navarro; VILELLA, Neysimelia Costa; MARTINHO, Glaucia Helena; VIEIRA, Ana Karine; KONDO, Andrea Tiemi; HAMERSCHLAK, Nelson; FILHO, Jayr Schmidt; XAVIER, Erick Menezes; FERNANDES, Juliana Folloni; ROCHA, Vanderson; COVAS, Dimas Tadeu; CALADO, Rodrigo Tocantins; GUERINO-CUNHA, Renato Luiz; SANTIS, Gil Cunha DeBackground: Steroid-refractory acute graft-vs.-host disease (SR-aGVHD) is a complication of allogeneic hematopoietic stem cell transplantation with a dismal prognosis and for which there is no consensus-based second-line therapy. Ruxolitinib is not easily accessible in many countries. A possible therapy is the administration of mesenchymal stromal cells (MSCs). Methods: In this retrospective study, 52 patients with severe SR-aGVHD were treated with MSCs from umbilical cord (UC-MSCs) in nine institutions. Results: The median (range) age was 12.5 (0.3-65) years and the mean +/- SD dose (x10(6)/kg) was 4.73 +/- 1.3 per infusion (median of four infusions). Overall (OR) and complete response (CR) rates on day 28 were 63.5% and 36.6%, respectively. Children (n = 35) had better OR (71.5% vs. 47.1%, p = 0.12), CR (48.6% vs. 11.8%, p = 0.03), overall survival (p = 0.0006), and relapse-free survival (p = 0.0014) than adults (n = 17). Acute adverse events (all of them mild or moderate) were detected in 32.7% of patients, with no significant difference in children and adult groups (p = 1.0). Conclusions: UC-MSCs are a feasible alternative therapy for SR-aGVHD, especially in children. The safety profile is favorable.
conferenceObject Chronic Graft-Versus-Host Disease in Double Cord Blood Transplantation According to National Institutes of Health 2005 Criteria: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party of the EBMT(2016) HAYASHI, Hiromi; RUGGERI, Annalisa; AYOUBI, Hanadi Rafii -El; CORNELISSEN, Jan J.; SOCIE, Gerard; ANDERSEN, Niels S.; MICHALLET, Mauricette; KARAKASIS, Dimitrios; PETERSEN, Eefke; VEELKEN, Joan Hendrik; CAHN, Jean Yves; ROHRLICH, Pierre-Simon; MERCIER, Melanie; VOLT, Fernanda; KENZEY, Chantal; XAVIER, Erick; ROCHA, Vanderson; GLUCKMAN, Eliane- Chronic graft-versus-host disease features in double unit cord blood transplantation according to National Institutes of Health 2005 cGVHD Consensus criteria(2018) HAYASHI, Hiromi; RUGGERI, Annalisa; VOLT, Fernanda; CORNELISSEN, Jan J.; SOCIE, Gerard; SENGELOEV, Henrik; MICHALLET, Mauricette; KARAKASIS, Dimitrios; PETERSEN, Eefke; CAHN, Jean Yves; VEELKEN, Hendrik; MERCIER, Melanie; ROHRLICH, Pierre-Simon; RAFII, Hanadi; KENZEY, Chantal; XAVIER, Erick; DUARTE, Rafael F.; BASAK, Grzegorz W.; ROCHA, Vanderson; GLUCKMAN, Eliane
conferenceObject Viral Reactivation after T-Cell Replete Haploidentical Transplantation Using Myeloablative Conditioning and Post-Transplant Cyclophosphamide(2016) BEZERRA, Evandro; SILVA, Roberto Luiz da; SCHMIDT FILHO, Jayr; SANTOS, Marina; NASCIMENTO, Marina; SIMOES, Aline; XAVIER, Erick; ALMEIDA, Manuella; MARIANO, Livia Caroline; FERNANDES, Pedro; MARQUES, Larissa; COSTA, Sylvia; SEBER, Adriana; MACEDO, Maria Cristina; MACHADO, Clarisse- Low Dose Ganciclovir for Cytomegalovirus Reactivation after Allogeneic HSCT Is a Feasible Option with Same Efficacy and Less Toxicity Than Regular Dose(2020) AZEVEDO, Roberta; MOLLA, Vinicius Campos; RAMOS, Jessica Fernandes; PONCIANO, Danilo Belchior; MORAES, Pedro Henrique Arruda De; FONSECA, Ana Rita Da; SEIWALD, Maria Cristina Nunez; SERPA, Mariana; FERREIRA, Aliana Meneses; SZOR, Roberta Shcolnik; LEONEL, Rayana Bomfim; XAVIER, Erick Menezes; TUCUNDUVA, Luciana; ROCHA, Vanderson; NOVIS, Yana; KALLAS, Esper; NUCCI, Marcio; ARRAIS-RODRIGUES, Celso
conferenceObject Fertility Outcomes after Allogeneic Hematopoietic Stem Cell Transplants Conditioned with Busulfan 4 Mg/Kg and Cyclophosphamide 200 Mg/Kg to Treat Severe Aplastic Anemia(2015) KERBAUY, Mariana Nassif; MARIANO, Livia Caroline Barbosa; MENEZES, Erick; DANTAS, Evandro; SOBRINHO, Jayr Schmidt; NASCIMENTO, Marina M.; SILVA, Roberto; MACEDO, Maria Cristina; GUALANDRO, Sandra; SEBER, Adriana- COVID-19 in hematopoietic stem-cell transplant recipients: A systematic review and meta-analysis of clinical characteristics and outcomes(2023) RANDI, Bruno Azevedo; HIGASHINO, Hermes Ryoiti; SILVA, Vinicius Ponzio da; XAVIER, Erick Menezes; ROCHA, Vanderson; COSTA, Silvia FigueiredoPatients who undergo hematopoietic stem-cell transplantation (HSCT) are more susceptible to developing severe forms of COVID-19 with an increased risk of mortality. The aim of this study was to analyze, by performing a systematic review and meta-analysis, all studies that evaluated COVID-19 in HSCT adult recipients and present clinical characteristics and outcomes. Studies were eligible for inclusion if they: (I) described the clinical characteristics of COVID-19 in adult (aged 18 years old or above) HSCT recipients; (II) described outcomes of COVID-19 in this population, mainly lethality; (III) were full-text articles. We searched MedLine, Embase, SCOPUS, LILACS and Web of Science for full-text studies that evaluated COVID-19 in adult HSCT patients until 26 Apr 2023. Two independent reviewers screened the articles and extracted the data. The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Studies Reporting Prevalence Data was used to assess quality of the included studies. Meta-analysis was performed and the pooled prevalence of severe/critical disease and of death with a 95% CI was calculated with the random-effects model. Sixteen studies were included; seven (43.7%) were multicenter. Most of the studies were from Europe (37.5%). All of them had a low risk of bias using the JBI Checklist. A total of 1186 patients were included. Allogeneic HSCT patients were the majority in most studies, with a total of 861 patients (72.5%). The symptomatic rate was 79.4%. The pooled prevalence of severe/critical COVID-19 was 24.0% (95% CI 0.13-0.36; I2 = 94%; n = 334/990). The pooled prevalence of death for the entire population was 17% (95% CI 0.13-0.22; I2 = 76%; n = 221/1117), 17% (95% CI 0.12-0.23; I2 = 67%; n = 152/822) for allogeneic-HSCT and 14% (95% CI 0.08-0.22; I4 = 65%; n = 48/293) for autologous-HSCT. In conclusion, frequently the infection of SARS-CoV-2 in HSCT was symptomatic and lethality is higher than in general population. Thus, it is essential to focus on the implementation of measures to mitigate the risk of SARS-CoV-2 infection in this population, as well as to carefully assess HSCT recipients who develop COVID-19.